213 related articles for article (PubMed ID: 31535302)
1. The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB-IIC Patients-Results After 3 Years.
Deckers EA; Hoekstra-Weebers JEHM; Damude S; Francken AB; Ter Meulen S; Bastiaannet E; Hoekstra HJ
Ann Surg Oncol; 2020 May; 27(5):1407-1417. PubMed ID: 31535302
[TBL] [Abstract][Full Text] [Related]
2. The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year.
Damude S; Hoekstra-Weebers JE; Francken AB; Ter Meulen S; Bastiaannet E; Hoekstra HJ
Ann Surg Oncol; 2016 Sep; 23(9):2762-71. PubMed ID: 27194552
[TBL] [Abstract][Full Text] [Related]
3. The MelFo Study UK: Effects of a Reduced-Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma 1B to 2C Patients After 3-Years.
Moncrieff MD; Underwood B; Garioch JJ; Heaton M; Patel N; Bastiaannet E; Hoekstra-Weebers JEHM; Hoekstra HJ
Ann Surg Oncol; 2020 Oct; 27(11):4109-4119. PubMed ID: 32623608
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma.
Podlipnik S; Moreno-Ramírez D; Carrera C; Barreiro A; Manubens E; Ferrandiz-Pulido L; Sánchez M; Vidal-Sicart S; Malvehy J; Puig S
Br J Dermatol; 2019 May; 180(5):1190-1197. PubMed ID: 29876940
[TBL] [Abstract][Full Text] [Related]
5. Follow-up Schedule for Patients With Sentinel Node-negative Cutaneous Melanoma (The MELFO Study): An International Phase III Randomized Clinical Trial.
Moncrieff MD; Bastiaannet E; Underwood B; Francken AB; Garioch J; Damude S; Heaton M; Deckers EA; Patel N; Hoekstra-Weebers JE; Hoekstra HJ
Ann Surg; 2022 Oct; 276(4):e208-e216. PubMed ID: 35866644
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma.
Turner RM; Bell KJ; Morton RL; Hayen A; Francken AB; Howard K; Armstrong B; Thompson JF; Irwig L
J Clin Oncol; 2011 Dec; 29(35):4641-6. PubMed ID: 22067399
[TBL] [Abstract][Full Text] [Related]
7. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
[TBL] [Abstract][Full Text] [Related]
8. ENdometrial cancer SURvivors' follow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial.
Ezendam NPM; de Rooij BH; Kruitwagen RFPM; Creutzberg CL; van Loon I; Boll D; Vos MC; van de Poll-Franse LV
Trials; 2018 Apr; 19(1):227. PubMed ID: 29661218
[TBL] [Abstract][Full Text] [Related]
9. Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis.
Stanelle EJ; Busam KJ; Rich BS; Christison-Lagay ER; Dunkel IJ; Marghoob AA; Halpern A; Coit DG; La Quaglia MP
J Pediatr Surg; 2015 Jun; 50(6):1019-23. PubMed ID: 25819019
[TBL] [Abstract][Full Text] [Related]
10. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.
Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC
Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365
[TBL] [Abstract][Full Text] [Related]
11. Follow-up schedules after treatment for malignant melanoma.
Francken AB; Accortt NA; Shaw HM; Colman MH; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF
Br J Surg; 2008 Nov; 95(11):1401-7. PubMed ID: 18844268
[TBL] [Abstract][Full Text] [Related]
12. [Follow-up for cutaneous melanoma].
Kettelhack C
Ther Umsch; 2008 Jun; 65(6):335-40. PubMed ID: 18622957
[TBL] [Abstract][Full Text] [Related]
13. Patient Preferences for Follow-up After Recent Excision of a Localized Melanoma.
Lim WY; Morton RL; Turner RM; Jenkins MC; Guitera P; Irwig L; Webster AC; Dieng M; Saw RPM; Low D; Low C; Bell KJL
JAMA Dermatol; 2018 Apr; 154(4):420-427. PubMed ID: 29490373
[TBL] [Abstract][Full Text] [Related]
14. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
15. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
16. ASO Author Reflections: The MelFo-Study, UK: Effects of a Reduced Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma IB-IIC Patients After 3 Years.
Moncrieff M; Underwood B; Garioch J; Heaton M; Patel N; Bastiaannet E; Hoekstra-Weebers J; Hoekstra H
Ann Surg Oncol; 2020 Oct; 27(11):4120-4121. PubMed ID: 32651698
[No Abstract] [Full Text] [Related]
17. Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.
Tan SY; Najita J; Li X; Strazzulla LC; Dunbar H; Lee MY; Seery VJ; Buchbinder EI; Tawa NE; McDermott DF; Lee SJ; Atkins MB; Kim CC
Melanoma Res; 2019 Feb; 29(1):70-76. PubMed ID: 30169431
[TBL] [Abstract][Full Text] [Related]
18. Single-institution experience in the management of patients with clinical stage I and II cutaneous melanoma: results of sentinel lymph node biopsy in 240 cases.
Rex J; Paradelo C; Mangas C; Hilari JM; Fernández-Figueras MT; Fraile M; Alastrué A; Ferrándiz C
Dermatol Surg; 2005 Nov; 31(11 Pt 1):1385-93. PubMed ID: 16416605
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589
[TBL] [Abstract][Full Text] [Related]
20. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
